Mydecine's research agreement with the University of Alberta is a key stepping-stone in expediting its psilocybin-based drug development research.
Psychedelics
MindMed To Evaluate Ayahuasca's Active Ingredient DMT In A Phase 1 Clinical Trial Collaboration
MindMed is adding to its clinical trials on psychedelics with a Phase 1 collaboration aimed at ayahuasca research.
What Does Field Trip Psychedelics Offer Investors?
Field Trip Psychedelics has just announced a letter of intent to go public via RTO.
GreenStar Biosciences Signs Agreement to Acquire 100% of Eleusian Biosciences Corp.
Greenstar Biosciences is entering the psychedelics space via its acquisition of Eleusian Biosciences Corp.
New Wave Holdings Appoints Dr. Dennis McKenna to Psychedelic Research Advisory Board
New Wave Holdings Corp has added a recognized expert in psychedelic medicine to the company's Advisory Board.
Champignon Brands Announces Regulatory Review, Cease Trade Order
Trading of Champignon Brands (SHRM) on the Canadian Securities Exchange has been temporarily halted due to the failure to file necessary disclosures with respect to recent acquisitions.
Mydecine Innovations Signs Definitive Agreement to Acquire Mindleap Health's Advanced Digital Telehealth Platform
Mydecine is acquiring the Digital Telehealth Platform of Mindleap Health Inc in a cash and shares deal.
North Sur Resources and Mindset Pharma Announce Proposed Transaction to Accelerate Development of Medical Psychedelics Industry
An amalgamation of two private companies as psychedelics company Mindset Pharma Inc prepares to go public.
Eleusis Looks For Alzheimer’s Breakthrough With Micro-Dosed LSD
Eleusis Therapeutics is a private psychedelics company that is turning a lot of heads with its research on micro-doses of LSD as a treatment for Alzheimer's.
Mydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical Innovation
Mydecine announces research agreement with a leading pharmacology research institution.
Mydecine Innovations Group Adds a Leading Neuroscientist and a Psychopharmacology Specialist
Mydecine's new Scientific Advisor will work directly with the CSO in new drug development initiatives.
Mydecine Innovations Group Adds Former Pfizer, Novartis, Yale Drug Discovery Expert to Scientific Advisory Board
Mydecine's new Scientific Advisor will work directly with the CSO in drug development initiatives.
Wuhan General Group Signs Manufacturing, Distribution and Sales Agreement with Cafféluxe
Wuhan General lines up capsule manufacturer, specializing in coffee pods.
Mira X Acquisition Corp. Announces Proposed Qualifying Transaction with Field Trip Psychedelics Inc
Field Trip Psychedelics is planning to go public via a "three-cornered" RTO.
Numinus announces Clinical Advisory Council to advance its integrated wellness model
Numinus' new Clinical Advisory Council will provide support for its psychedelic drug R&D at all levels.